End-of-day quote
INDONESIA S.E.
07:00:00 2024-03-27 pm EDT
5-day change
1st Jan Change
1,475
IDR
+1.03%
-0.34%
-8.39%
Sales 2023 *
30,922B
1.95B
Sales 2024 *
33,014B
2.08B
Capitalization
68,227B
4.3B
Net income 2023 *
2,828B
178M
Net income 2024 *
3,460B
218M
EV / Sales 2023 *
2.07
x
Net cash position
2023
*
4,191B
264M
Net cash position
2024
*
5,518B
348M
EV / Sales 2024 *
1.9
x P/E ratio 2023 *
24.2
x
P/E ratio 2024 *
20
x
Employees
13,134
Yield 2023 *
2.29%
Yield 2024 *
2.12%
Free-Float
40.45%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-06
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-28
CI
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Progen Co. Ltd. announced that it has received IDR 155.72 billion in funding from PT Kalbe Farma Tbk.
23-01-01
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-30
CI
PT Kalbe Farma Tbk. completed the acquisition of a 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-10-25
CI
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
PT Kalbe Farma Tbk. Reports Earnings Results for the Half Year Ended June 30, 2022
22-07-28
CI
PT Kalbe Farma Tbk. entered into agreement to acquire 80% stake in PT Aventis Pharma from Hoechst GmbH and Sanofi-Aventis Participations S.A.S.
22-07-24
CI
PT Kalbe Farma Tbk.'s Equity Buyback announced on February 10, 2022, has expired.
22-05-07
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-28
CI
PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-30
CI
More news
Nomura Adjusts Kalbe Farma’s Price Target to IDR1,850 From IDR2,500, Keeps at Buy
Feb. 20
MT
Nomura Adjusts Kalbe Farma’s Price Target to IDR2,500 From IDR2,250, Keeps at Buy
23-01-30
MT
Nomura Adjusts Kalbe Farma's Price Target to 2,250 Rupiahs From 1,905 Rupiahs, Keeps at Buy
22-09-22
MT
Nomura Adjusts Kalbe Farma's Price Target to 1,905 Indonesian Rupiahs From1,550 Indonesian Rupiahs, Keeps at Buy
22-01-11
MT
PT KALBE FARMA TBK : Nomura Adjusts Kalbe Farma's Price Target to 1,550 Indonesian Rupiahs From 1,900 Indonesian Rupiahs, Keeps at Buy
21-08-12
MT
More recommendations
1 day +1.03%
1 week -0.34%
Current month -1.01%
1 month +1.03%
3 months -8.95%
6 months -15.95%
Current year -8.39%
More quotes
Managers
Title Age Since
Chief Executive Officer
59
96-12-31
Director of Finance/CFO
-
17-01-31
Chairman
61
97-02-28
Members of the board
Title Age Since
Director/Board Member
59
99-12-31
Director/Board Member
51
07-12-31
Chairman
61
97-02-28
More insiders
Date
Price
Change
Volume
24-03-28
1,475
+1.03%
30,183,200
24-03-27
1,460
-2.99%
20,490,100
24-03-26
1,505
-0.99%
32,682,200
24-03-25
1,520
+2.36%
22,175,400
24-03-22
1,485
+1.71%
23,371,300
End-of-day quote
INDONESIA S.E., March 27, 2024
More quotes
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
More about the company
Last Close Price
1,475
IDR
Average target price
1,788
IDR
Spread / Average Target
+21.22%
Consensus
1st Jan change
Capi.
-8.39% 4.25B +33.46% 701B +26.24% 571B +0.93% 381B +21.03% 334B +17.51% 319B +0.74% 210B +2.95% 210B -6.05% 201B -3.61% 157B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1